Open AccessClinical use of insulin degludec: Practical experience and pragmatic suggestions
Author(s) -
Sanjay Kalra,
Yashdeep Gupta
Publication year - 2015
Publication title -
north american journal of medical sciences
Language(s) - English
Resource type - Journals
eISSN - 2250-1541
pISSN - 1947-2714
DOI - 10.4103/1947-2714.153918
Subject(s) - insulin degludec , medicine , insulin analog , hypoglycemia , basal insulin , pharmacodynamics , intensive care medicine , insulin , insulin glargine , diabetes mellitus , pharmacokinetics , endocrinology , type 2 diabetes , human insulin
Insulin degludec (IDeg) is an ultralong acting basal insulin. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia. This review discusses the pragmatic use of IDeg, based on available evidence. A complete search of all nine original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed, was made to prepare this article.